Skip to content
Dose Brief
Menu
No. 88 on the board · Grade C

Hers review

Women-focused telehealth brand from Hims and Hers offering compounded semaglutide on a 6-month plan.

Visit Hers Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the score.
Semaglutide
From $199/mo (starting dose, compounded)
Tirzepatide
From $299/mo (starting dose, plus a separate fee, brand-name)
Coverage
All 50 states
Brand-name
Yes
On the trackerNewnew to the tracker, no prior readingNew to the tracker on 1 August 2026. The published line reads From $199/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

The scorecard

Hers scored on our six Brief Score factors. See the methodology.

Price Stability48/100
Supply Reliability74/100
Transparency88/100
Access Breadth96/100
Clinical Oversight71/100
Track Record77/100

What we like

  • Compounded GLP-1 access

The caveats

  • Limited public information on program details

The brief

Best for: Readers who want mainstream telehealth GLP-1 access. Women-focused telehealth brand from Hims and Hers offering compounded semaglutide on a 6-month plan.

Ranked #88 of 495 providers we reviewed — see our #1 pick, CoreAge Rx, for comparison.

Closest on the board

The desks scoring nearest Hers — the realistic shortlist if you're weighing it.

Weighing Hers against one desk in particular? We file it head to head with our top-ranked pick in CoreAge Rx vs Hers, and every desk that outranks it is listed on the Hers alternatives board.

More desks we track (24)

464 more are filed too — see every desk we track, ranked.

Pricing, states and verification reflect Hers's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on Hers's site. Not medical advice; see our disclosure.

← Back to all rankings